217 papers
Understanding the human mind and treating mental health conditions requires a deep blend of biological insight and behavioral science. This category explores the cutting-edge research shaping how we diagnose and treat psychiatric disorders, from depression and anxiety to complex neurological conditions. Here, you will find the latest discoveries that bridge the gap between clinical observation and molecular mechanisms, offering fresh perspectives on patient care and therapeutic innovation.
Gist.Science brings these vital studies directly to you by monitoring medRxiv, the leading preprint server for health sciences. As soon as new manuscripts appear in this field, our team processes them to provide both accessible plain-language summaries and detailed technical overviews. This ensures that complex findings are understandable for everyone, from curious readers to busy professionals who need quick, accurate insights without wading through dense academic prose.
Below are the most recent psychiatry and clinical psychology preprints, curated and summarized to keep you informed on the evolving landscape of mental health research.
The TIDE study protocol outlines a prospective clinical cohort investigation designed to assess the feasibility of daily symptom tracking, estimate the prevalence of premenstrual exacerbation (PME) in women with depression, and explore its association with other hormone-related mood symptoms.
A pooled analysis of 536 psilocybin sessions across 14 studies reveals that the drug causes only modest, transient blood pressure elevations comparable to moderate exercise, suggesting that current cardiovascular exclusion criteria are overly conservative and should be broadened to include individuals with baseline blood pressure under 160/100 mmHg.
This study of Uganda's first specialized early intervention service for psychosis reveals that while clinical outcomes improve rapidly once patients are enrolled, complex cultural pathways and significant delays—particularly involving initial contact with native healers—lead to substantial attrition, highlighting the urgent need to strengthen referral systems and reduce care delays in low-resource settings.
This study reports that a secondary analysis of a randomized controlled trial found no evidence that neurofeedback treatment improves sustained attention, inhibitory control, or associated neural markers in adults with ADHD compared to a waitlist control group.
This qualitative study of 33 clinicians reveals that while patient-generated streaming data offers valuable longitudinal insights for mental health care, its meaningful integration into routine practice is currently hindered by significant barriers including workflow constraints, poor electronic record integration, data reliability concerns, and regulatory uncertainties.
This study of a South African birth cohort reveals that while nearly all children experienced violence by age eight, recent exposure is more strongly associated with mental health problems and psychiatric disorders than early-life exposure, with domestic violence showing the most consistent negative impact.
This fully remote randomized controlled trial demonstrates that an ultra-brief, 10-minute daily digital meditation intervention significantly reduces internalizing symptoms like anxiety and mind wandering in non-clinical adults, with the most pronounced benefits observed among those with higher baseline symptom burdens.
In a randomized controlled trial involving 53 patients with major depressive disorder and 45 controls, transcutaneous vagus nerve stimulation (tVNS) was found to specifically enhance reward-effort efficiency in individuals with severe depressive symptoms by reducing unnecessary physical effort, suggesting a potential motivational mechanism for its therapeutic effects.
This systematic review and meta-analysis of 56 controlled trials demonstrates that gamma neuromodulation provides moderate therapeutic benefits for symptoms in schizophrenia and major depressive disorder, though substantial heterogeneity underscores the need for standardized protocols in future research.
This open-label feasibility trial demonstrates that personalized, connectivity-guided, accelerated intermittent theta-burst stimulation (iTBS) induces rapid and sustained antidepressant effects in patients with both treatment-resistant and ultra-treatment-resistant depression, offering a safe and effective option for individuals who have failed multiple prior therapies.